Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 9985 to 9996 of 67709 entries
Sorted by: Best Match Show Resources per page
Targeted Drugs Fall Short in Squamous Lung Cancer.

Cancer discovery

[No authors listed]
PMID: 33218972
Cancer Discov. 2021 Jan;11(1):OF3. doi: 10.1158/2159-8290.CD-NB2020-107. Epub 2020 Nov 20.

A massive 5 year-plus effort to find molecularly targeted therapies for patients with recurrent, advanced-stage squamous cell carcinoma of the lungs has demonstrated the feasibility of rapidly screening tumors for rare genomic alterations and assigning drug treatments accordingly. Yet,...

Cite
Targeted Drugs Fall Short in Squamous Lung Cancer. Cancer Discov. 2020;11(1):OF3doi: 10.1158/2159-8290.CD-NB2020-107.
(2021). Targeted Drugs Fall Short in Squamous Lung Cancer. Cancer discovery, 11(1), OF3. https://doi.org/10.1158/2159-8290.CD-NB2020-107
"Targeted Drugs Fall Short in Squamous Lung Cancer." Cancer discovery vol. 11,1 (2021): OF3. doi: https://doi.org/10.1158/2159-8290.CD-NB2020-107
Targeted Drugs Fall Short in Squamous Lung Cancer. Cancer Discov. 2021 Jan;11(1):OF3. doi: 10.1158/2159-8290.CD-NB2020-107. Epub 2020 Nov 20. PMID: 33218972.
Copy Download .nbib Format: NLM
Efficacy of Surgical Excision and Adjuvant High-dose Rate Brachytherapy in Treatment of Keloid: Our Experience.

Journal of cutaneous and aesthetic surgery

Manjunath KN, Venkatesh MS, Alva R, Koushik K, Waiker V, Mohan K, Shivalingappa S.
PMID: 34908777
J Cutan Aesthet Surg. 2021 Jul-Sep;14(3):337-343. doi: 10.4103/JCAS.JCAS_120_16.

BACKGROUND: Keloids are dermal tumors that are due to increased production of collagen caused by abnormal and prolonged wound healing. The incidence of recurrence is extremely high if only conservative measures are used. This study was conducted to evaluate...

Cite
Manjunath KN, Venkatesh MS, Alva R, et al. Efficacy of Surgical Excision and Adjuvant High-dose Rate Brachytherapy in Treatment of Keloid: Our Experience. J Cutan Aesthet Surg. 2021;14(3):337-343doi: 10.4103/JCAS.JCAS_120_16.
Manjunath, K. N., Venkatesh, M. S., Alva, R., Koushik, K., Waiker, V., Mohan, K., & Shivalingappa, S. (2021). Efficacy of Surgical Excision and Adjuvant High-dose Rate Brachytherapy in Treatment of Keloid: Our Experience. Journal of cutaneous and aesthetic surgery, 14(3), 337-343. https://doi.org/10.4103/JCAS.JCAS_120_16
Manjunath, Kalapurmat N, et al. "Efficacy of Surgical Excision and Adjuvant High-dose Rate Brachytherapy in Treatment of Keloid: Our Experience." Journal of cutaneous and aesthetic surgery vol. 14,3 (2021): 337-343. doi: https://doi.org/10.4103/JCAS.JCAS_120_16
Manjunath KN, Venkatesh MS, Alva R, Koushik K, Waiker V, Mohan K, Shivalingappa S. Efficacy of Surgical Excision and Adjuvant High-dose Rate Brachytherapy in Treatment of Keloid: Our Experience. J Cutan Aesthet Surg. 2021 Jul-Sep;14(3):337-343. doi: 10.4103/JCAS.JCAS_120_16. PMID: 34908777; PMCID: PMC8611697.
Copy Download .nbib Format: NLM
Aspirin as an Adjunctive Pharmacologic Therapy Option for COVID-19: Anti-Inflammatory, Antithrombotic, and Antiviral Effects All in One Agent.

Journal of experimental pharmacology

Tantry US, Schror K, Navarese EP, Jeong YH, Kubica J, Bliden KP, Gurbel PA.
PMID: 34908882
J Exp Pharmacol. 2021 Dec 07;13:957-970. doi: 10.2147/JEP.S330776. eCollection 2021.

INTRODUCTION: Pharmacologic therapy options for COVID-19 should include antiviral, anti-inflammatory, and anticoagulant agents. With the limited effectiveness, currently available virus-directed therapies may have a substantial impact on global health due to continued reports of mutant variants affecting repeated waves...

Cite
Tantry US, Schror K, Navarese EP, et al. Aspirin as an Adjunctive Pharmacologic Therapy Option for COVID-19: Anti-Inflammatory, Antithrombotic, and Antiviral Effects All in One Agent. J Exp Pharmacol. 2021;13:957-970doi: 10.2147/JEP.S330776.
Tantry, U. S., Schror, K., Navarese, E. P., Jeong, Y. H., Kubica, J., Bliden, K. P., & Gurbel, P. A. (2021). Aspirin as an Adjunctive Pharmacologic Therapy Option for COVID-19: Anti-Inflammatory, Antithrombotic, and Antiviral Effects All in One Agent. Journal of experimental pharmacology, 13957-970. https://doi.org/10.2147/JEP.S330776
Tantry, Udaya S, et al. "Aspirin as an Adjunctive Pharmacologic Therapy Option for COVID-19: Anti-Inflammatory, Antithrombotic, and Antiviral Effects All in One Agent." Journal of experimental pharmacology vol. 13 (2021): 957-970. doi: https://doi.org/10.2147/JEP.S330776
Tantry US, Schror K, Navarese EP, Jeong YH, Kubica J, Bliden KP, Gurbel PA. Aspirin as an Adjunctive Pharmacologic Therapy Option for COVID-19: Anti-Inflammatory, Antithrombotic, and Antiviral Effects All in One Agent. J Exp Pharmacol. 2021 Dec 07;13:957-970. doi: 10.2147/JEP.S330776. eCollection 2021. PMID: 34908882; PMCID: PMC8665864.
Copy Download .nbib Format: NLM
Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis .

Acta pharmaceutica Sinica. B

Deng L, Petrek H, Tu MJ, Batra N, Yu AX, Yu AM.
PMID: 35024318
Acta Pharm Sin B. 2021 Dec;11(12):3950-3965. doi: 10.1016/j.apsb.2021.07.027. Epub 2021 Aug 17.

With the understanding of microRNA (miRNA or miR) functions in tumor initiation, progression, and metastasis, efforts are underway to develop new miRNA-based therapies. Very recently, we demonstrated effectiveness of a novel humanized bioengineered miR-124-3p prodrug in controlling spontaneous lung...

Cite
Deng L, Petrek H, Tu MJ, et al. Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis . Acta Pharm Sin B. 2021;11(12):3950-3965doi: 10.1016/j.apsb.2021.07.027.
Deng, L., Petrek, H., Tu, M. J., Batra, N., Yu, A. X., & Yu, A. M. (2021). Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis . Acta pharmaceutica Sinica. B, 11(12), 3950-3965. https://doi.org/10.1016/j.apsb.2021.07.027
Deng, Linglong, et al. "Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis ." Acta pharmaceutica Sinica. B vol. 11,12 (2021): 3950-3965. doi: https://doi.org/10.1016/j.apsb.2021.07.027
Deng L, Petrek H, Tu MJ, Batra N, Yu AX, Yu AM. Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis . Acta Pharm Sin B. 2021 Dec;11(12):3950-3965. doi: 10.1016/j.apsb.2021.07.027. Epub 2021 Aug 17. PMID: 35024318; PMCID: PMC8727917.
Copy Download .nbib Format: NLM
Carbon nitride nanomaterials with application in photothermal and photodynamic therapies.

Photodiagnosis and photodynamic therapy

Bosio GN, Mártire DO.
PMID: 34915184
Photodiagnosis Photodyn Ther. 2021 Dec 13;37:102683. doi: 10.1016/j.pdpdt.2021.102683. Epub 2021 Dec 13.

Phototherapies offer treatment of tumors with high spatial selectivity. Photodynamic therapy (PDT) consists in the administration of a photosensitizer (PS) followed by local photoirradiation with light of specific wavelength. The excited states of the PS interact with biomolecules and...

Cite
Bosio GN, Mártire DO. Carbon nitride nanomaterials with application in photothermal and photodynamic therapies. Photodiagnosis Photodyn Ther. 2021;37:102683doi: 10.1016/j.pdpdt.2021.102683.
Bosio, G. N., & Mártire, D. O. (2021). Carbon nitride nanomaterials with application in photothermal and photodynamic therapies. Photodiagnosis and photodynamic therapy, 37102683. https://doi.org/10.1016/j.pdpdt.2021.102683
Bosio, Gabriela N, and Mártire, Daniel O. "Carbon nitride nanomaterials with application in photothermal and photodynamic therapies." Photodiagnosis and photodynamic therapy vol. 37 (2021): 102683. doi: https://doi.org/10.1016/j.pdpdt.2021.102683
Bosio GN, Mártire DO. Carbon nitride nanomaterials with application in photothermal and photodynamic therapies. Photodiagnosis Photodyn Ther. 2021 Dec 13;37:102683. doi: 10.1016/j.pdpdt.2021.102683. Epub 2021 Dec 13. PMID: 34915184.
Copy Download .nbib Format: NLM
Editorial Comment: Tailored Therapies in Patients With HER2+ Breast Cancer Could be Achieved by Using TIL Predictors, Significantly Improving Patient Outcomes.

AJR. American journal of roentgenology

Papalouka V.
PMID: 34494450
AJR Am J Roentgenol. 2021 Sep 08; doi: 10.2214/AJR.21.26749. Epub 2021 Sep 08.

No abstract available.

Cite
Papalouka V. Editorial Comment: Tailored Therapies in Patients With HER2+ Breast Cancer Could be Achieved by Using TIL Predictors, Significantly Improving Patient Outcomes. AJR Am J Roentgenol. 2021;doi: 10.2214/AJR.21.26749.
Papalouka, V. (2021). Editorial Comment: Tailored Therapies in Patients With HER2+ Breast Cancer Could be Achieved by Using TIL Predictors, Significantly Improving Patient Outcomes. AJR. American journal of roentgenology, . https://doi.org/10.2214/AJR.21.26749
Papalouka, Vasiliki. "Editorial Comment: Tailored Therapies in Patients With HER2+ Breast Cancer Could be Achieved by Using TIL Predictors, Significantly Improving Patient Outcomes." AJR. American journal of roentgenology vol. (2021). doi: https://doi.org/10.2214/AJR.21.26749
Papalouka V. Editorial Comment: Tailored Therapies in Patients With HER2+ Breast Cancer Could be Achieved by Using TIL Predictors, Significantly Improving Patient Outcomes. AJR Am J Roentgenol. 2021 Sep 08; doi: 10.2214/AJR.21.26749. Epub 2021 Sep 08. PMID: 34494450.
Copy Download .nbib Format: NLM
Prospects for Clinical Development of Stat5 Inhibitor IST5-002: High Transcriptomic Specificity in Prostate Cancer and Low Toxicity In Vivo.

Cancers

Maranto C, Udhane V, Jia J, Verma R, Müller-Newen G, LaViolette PS, Pereckas M, Sabharwal L, Terhune S, Pattabiraman N, Njar VCO, Imig JD, Wang L, Nevalainen MT.
PMID: 33217941
Cancers (Basel). 2020 Nov 18;12(11). doi: 10.3390/cancers12113412.

Stat5 is of significant interest in the search for new therapeutics for prostate cancer (PC) and hematopoietic disorders. We evaluated the transcriptomic specificity of the Stat5a/b inhibitor IST5-002 (IST5) in PC, defined more closely its mechanisms of action, and...

Cite
Maranto C, Udhane V, Jia J, et al. Prospects for Clinical Development of Stat5 Inhibitor IST5-002: High Transcriptomic Specificity in Prostate Cancer and Low Toxicity In Vivo. Cancers (Basel). 2020;12(11)doi: 10.3390/cancers12113412.
Maranto, C., Udhane, V., Jia, J., Verma, R., Müller-Newen, G., LaViolette, P. S., Pereckas, M., Sabharwal, L., Terhune, S., Pattabiraman, N., Njar, V. C. O., Imig, J. D., Wang, L., & Nevalainen, M. T. (2020). Prospects for Clinical Development of Stat5 Inhibitor IST5-002: High Transcriptomic Specificity in Prostate Cancer and Low Toxicity In Vivo. Cancers, 12(11), . https://doi.org/10.3390/cancers12113412
Maranto, Cristina, et al. "Prospects for Clinical Development of Stat5 Inhibitor IST5-002: High Transcriptomic Specificity in Prostate Cancer and Low Toxicity In Vivo." Cancers vol. 12,11 (2020). doi: https://doi.org/10.3390/cancers12113412
Maranto C, Udhane V, Jia J, Verma R, Müller-Newen G, LaViolette PS, Pereckas M, Sabharwal L, Terhune S, Pattabiraman N, Njar VCO, Imig JD, Wang L, Nevalainen MT. Prospects for Clinical Development of Stat5 Inhibitor IST5-002: High Transcriptomic Specificity in Prostate Cancer and Low Toxicity In Vivo. Cancers (Basel). 2020 Nov 18;12(11). doi: 10.3390/cancers12113412. PMID: 33217941; PMCID: PMC7724566.
Copy Download .nbib Format: NLM
Agonistic CD40 Antibodies in Cancer Treatment.

Cancers

Djureinovic D, Wang M, Kluger HM.
PMID: 33804039
Cancers (Basel). 2021 Mar 15;13(6). doi: 10.3390/cancers13061302.

CD40 is expressed on a variety of antigen-presenting cells. Stimulation of CD40 results in inflammation by upregulation of other costimulatory molecules, increased antigen presentation, maturation (licensing) of dendritic cells, and activation of CD8+ T cells. Here we analyzed gene...

Cite
Djureinovic D, Wang M, Kluger HM. Agonistic CD40 Antibodies in Cancer Treatment. Cancers (Basel). 2021;13(6)doi: 10.3390/cancers13061302.
Djureinovic, D., Wang, M., & Kluger, H. M. (2021). Agonistic CD40 Antibodies in Cancer Treatment. Cancers, 13(6), . https://doi.org/10.3390/cancers13061302
Djureinovic, Dijana, et al. "Agonistic CD40 Antibodies in Cancer Treatment." Cancers vol. 13,6 (2021). doi: https://doi.org/10.3390/cancers13061302
Djureinovic D, Wang M, Kluger HM. Agonistic CD40 Antibodies in Cancer Treatment. Cancers (Basel). 2021 Mar 15;13(6). doi: 10.3390/cancers13061302. PMID: 33804039; PMCID: PMC8000216.
Copy Download .nbib Format: NLM
Chemoinformatic Analysis of Psychotropic and Antihistaminic Drugs in the Light of Experimental Anti-SARS-CoV-2 Activities.

Advances and applications in bioinformatics and chemistry : AABC

Villoutreix BO, Krishnamoorthy R, Tamouza R, Leboyer M, Beaune P.
PMID: 33880039
Adv Appl Bioinform Chem. 2021 Apr 12;14:71-85. doi: 10.2147/AABC.S304649. eCollection 2021.

INTRODUCTION: There is an urgent need to identify therapies that prevent SARS-CoV-2 infection and improve the outcome of COVID-19 patients.OBJECTIVE: Based upon clinical observations, we proposed that some psychotropic and antihistaminic drugs could protect psychiatric patients from SARS-CoV-2 infection....

Cite
Villoutreix BO, Krishnamoorthy R, Tamouza R, et al. Chemoinformatic Analysis of Psychotropic and Antihistaminic Drugs in the Light of Experimental Anti-SARS-CoV-2 Activities. Adv Appl Bioinform Chem. 2021;14:71-85doi: 10.2147/AABC.S304649.
Villoutreix, B. O., Krishnamoorthy, R., Tamouza, R., Leboyer, M., & Beaune, P. (2021). Chemoinformatic Analysis of Psychotropic and Antihistaminic Drugs in the Light of Experimental Anti-SARS-CoV-2 Activities. Advances and applications in bioinformatics and chemistry : AABC, 1471-85. https://doi.org/10.2147/AABC.S304649
Villoutreix, Bruno O, et al. "Chemoinformatic Analysis of Psychotropic and Antihistaminic Drugs in the Light of Experimental Anti-SARS-CoV-2 Activities." Advances and applications in bioinformatics and chemistry : AABC vol. 14 (2021): 71-85. doi: https://doi.org/10.2147/AABC.S304649
Villoutreix BO, Krishnamoorthy R, Tamouza R, Leboyer M, Beaune P. Chemoinformatic Analysis of Psychotropic and Antihistaminic Drugs in the Light of Experimental Anti-SARS-CoV-2 Activities. Adv Appl Bioinform Chem. 2021 Apr 12;14:71-85. doi: 10.2147/AABC.S304649. eCollection 2021. PMID: 33880039; PMCID: PMC8051956.
Copy Download .nbib Format: NLM
Regenerative medicine and traumatic brain injury: from stem cell to cell-free therapeutic strategies.

Regenerative medicine

Cui L, Saeed Y, Li H, Yang J.
PMID: 34905963
Regen Med. 2022 Jan;17(1):37-53. doi: 10.2217/rme-2021-0069. Epub 2021 Dec 15.

Traumatic brain injury (TBI) is a serious health concern, yet there is a lack of standardized treatment to combat its long-lasting effects. The objective of the present study was to provide an overview of the limitation of conventional stem-cell...

Cite
Cui L, Saeed Y, Li H, et al. Regenerative medicine and traumatic brain injury: from stem cell to cell-free therapeutic strategies. Regen Med. 2021;17(1):37-53doi: 10.2217/rme-2021-0069.
Cui, L., Saeed, Y., Li, H., & Yang, J. (2022). Regenerative medicine and traumatic brain injury: from stem cell to cell-free therapeutic strategies. Regenerative medicine, 17(1), 37-53. https://doi.org/10.2217/rme-2021-0069
Cui, Lianxu, et al. "Regenerative medicine and traumatic brain injury: from stem cell to cell-free therapeutic strategies." Regenerative medicine vol. 17,1 (2022): 37-53. doi: https://doi.org/10.2217/rme-2021-0069
Cui L, Saeed Y, Li H, Yang J. Regenerative medicine and traumatic brain injury: from stem cell to cell-free therapeutic strategies. Regen Med. 2022 Jan;17(1):37-53. doi: 10.2217/rme-2021-0069. Epub 2021 Dec 15. PMID: 34905963.
Copy Download .nbib Format: NLM
Recanalisation therapies for acute ischaemic stroke in patients on direct oral anticoagulants.

Journal of neurology, neurosurgery, and psychiatry

Seiffge DJ, Meinel T, Purrucker JC, Kaesmacher J, Fischer U, Wilson D, Wu TY.
PMID: 33542084
J Neurol Neurosurg Psychiatry. 2021 May;92(5):534-541. doi: 10.1136/jnnp-2020-325456. Epub 2021 Feb 04.

Direct oral anticoagulants (DOACs) have emerged as primary therapeutic option for stroke prevention in patients with atrial fibrillation. However, patients may have ischaemic stroke despite DOAC therapy and there is uncertainty whether those patients can safely receive intravenous thrombolysis...

Cite
Seiffge DJ, Meinel T, Purrucker JC, et al. Recanalisation therapies for acute ischaemic stroke in patients on direct oral anticoagulants. J Neurol Neurosurg Psychiatry. 2021;92(5):534-541doi: 10.1136/jnnp-2020-325456.
Seiffge, D. J., Meinel, T., Purrucker, J. C., Kaesmacher, J., Fischer, U., Wilson, D., & Wu, T. Y. (2021). Recanalisation therapies for acute ischaemic stroke in patients on direct oral anticoagulants. Journal of neurology, neurosurgery, and psychiatry, 92(5), 534-541. https://doi.org/10.1136/jnnp-2020-325456
Seiffge, David J, et al. "Recanalisation therapies for acute ischaemic stroke in patients on direct oral anticoagulants." Journal of neurology, neurosurgery, and psychiatry vol. 92,5 (2021): 534-541. doi: https://doi.org/10.1136/jnnp-2020-325456
Seiffge DJ, Meinel T, Purrucker JC, Kaesmacher J, Fischer U, Wilson D, Wu TY. Recanalisation therapies for acute ischaemic stroke in patients on direct oral anticoagulants. J Neurol Neurosurg Psychiatry. 2021 May;92(5):534-541. doi: 10.1136/jnnp-2020-325456. Epub 2021 Feb 04. PMID: 33542084; PMCID: PMC8053326.
Copy Download .nbib Format: NLM
A New Platinum-Based Prodrug Candidate for Chemotherapy and Its Synergistic Effect With Hadrontherapy: Novel Strategy to Treat Glioblastoma.

Frontiers in neuroscience

Ferrari B, Roda E, Priori EC, De Luca F, Facoetti A, Ravera M, Brandalise F, Locatelli CA, Rossi P, Bottone MG.
PMID: 33828444
Front Neurosci. 2021 Mar 22;15:589906. doi: 10.3389/fnins.2021.589906. eCollection 2021.

Glioblastoma (GBM) is the most common tumor of the central nervous system. Current therapies, often associated with severe side effects, are inefficacious to contrast the GBM relapsing forms. In trying to overcome these drawbacks, (

Cite
Ferrari B, Roda E, Priori EC, et al. A New Platinum-Based Prodrug Candidate for Chemotherapy and Its Synergistic Effect With Hadrontherapy: Novel Strategy to Treat Glioblastoma. Front Neurosci. 2021;15:589906doi: 10.3389/fnins.2021.589906.
Ferrari, B., Roda, E., Priori, E. C., De Luca, F., Facoetti, A., Ravera, M., Brandalise, F., Locatelli, C. A., Rossi, P., & Bottone, M. G. (2021). A New Platinum-Based Prodrug Candidate for Chemotherapy and Its Synergistic Effect With Hadrontherapy: Novel Strategy to Treat Glioblastoma. Frontiers in neuroscience, 15589906. https://doi.org/10.3389/fnins.2021.589906
Ferrari, Beatrice, et al. "A New Platinum-Based Prodrug Candidate for Chemotherapy and Its Synergistic Effect With Hadrontherapy: Novel Strategy to Treat Glioblastoma." Frontiers in neuroscience vol. 15 (2021): 589906. doi: https://doi.org/10.3389/fnins.2021.589906
Ferrari B, Roda E, Priori EC, De Luca F, Facoetti A, Ravera M, Brandalise F, Locatelli CA, Rossi P, Bottone MG. A New Platinum-Based Prodrug Candidate for Chemotherapy and Its Synergistic Effect With Hadrontherapy: Novel Strategy to Treat Glioblastoma. Front Neurosci. 2021 Mar 22;15:589906. doi: 10.3389/fnins.2021.589906. eCollection 2021. PMID: 33828444; PMCID: PMC8019820.
Copy Download .nbib Format: NLM
Showing 9985 to 9996 of 67709 entries